相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cost-effectiveness of Teriflunomide Compared to Interferon Beta-1b for Relapsing Multiple Sclerosis Patients in China
Yan Xu et al.
CLINICAL DRUG INVESTIGATION (2019)
Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan
Masahiro Kobayashi et al.
JOURNAL OF GASTROENTEROLOGY (2019)
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion A Randomized Clinical Trial
MinKe He et al.
JAMA ONCOLOGY (2019)
A Systematic Review of Orthopedic Global Outreach Efforts Based on WHO-CHOICE Thresholds
Michael T. Nolte et al.
HAND CLINICS (2019)
Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China
Xiaohua Gu et al.
LUNG CANCER (2019)
Phase II Study of Sorafenib Combined with Concurrent Hepatic Arterial Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin for Unresectable Hepatocellular Carcinoma with Major Portal Vein Thrombosis
Min-Ke He et al.
CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY (2018)
Cost-benefit analysis of enhanced recovery after hepatectomy in Chinese Han population
Xiaolin Jing et al.
MEDICINE (2018)
Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US
Ralph P. Insinga et al.
JOURNAL OF MEDICAL ECONOMICS (2018)
Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China
Shukui Qin et al.
COST EFFECTIVENESS AND RESOURCE ALLOCATION (2018)
The lack of Raf-1 kinase feedback regulation enhances antiapoptosis in cancer cells
S. Q. Ma et al.
ONCOGENE (2017)
Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China
Shun Lu et al.
ONCOTARGET (2017)
RAS testing and cetuximab treatment for metastatic colorectal cancer: a cost-effectiveness analysis in a setting with limited health resources
Bin Wu et al.
ONCOTARGET (2017)
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015 A Systematic Analysis for the Global Burden of Disease Study
Christina Fitzmaurice et al.
JAMA ONCOLOGY (2017)
Prediction of Hepatocellular Carcinoma Recurrence Beyond Milan Criteria After Resection
Jian Zheng et al.
ANNALS OF SURGERY (2017)
Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial
M. Ikeda et al.
ANNALS OF ONCOLOGY (2016)
FOLFOX4 or sorafenib as the first-line treatments for advanced hepatocellular carcinoma: A cost-effectiveness analysis
Pengfei Zhang et al.
DIGESTIVE AND LIVER DISEASE (2016)
Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion
Takashi Kokudo et al.
JOURNAL OF HEPATOLOGY (2016)
Trial-Based Cost-Utility Analysis of Icotinib versus Gefitinib as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer in China
Chunxiang Zhang et al.
PLOS ONE (2016)
Appropriate treatment strategies for intrahepatic recurrence after curative resection of hepatocellular carcinoma initially within the Milan criteria: according to the recurrence pattern
Xiaoyun Zhang et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2015)
A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis
Do Seon Song et al.
JOURNAL OF GASTROENTEROLOGY (2015)
Practical Effect of Sorafenib Monotherapy on Advanced Hepatocellular Carcinoma and Portal Vein Tumor Thrombosis
Soung Won Jeong et al.
GUT AND LIVER (2013)
Modulation of the ATPase and Transport Activities of Broad-Acting Multidrug Resistance Factor ABCC10 (MRP7)
Ekaterina V. Malofeeva et al.
CANCER RESEARCH (2012)
The diffusion-weighted imaging perfusion fraction f is a potential marker of sorafenib treatment in advanced hepatocellular carcinoma: a pilot study
Maiete Lewin et al.
EUROPEAN RADIOLOGY (2011)
Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma
Beom Kyung Kim et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2011)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
Cost-Effectiveness Analysis of Adjuvant Therapy for Operable Breast Cancer from a Chinese Perspective Doxorubicin plus Cyclophosphamide versus Docetaxel plus Cyclophosphamide
Peng Liubao et al.
PHARMACOECONOMICS (2009)
Health state utilities for non small cell lung cancer
Beenish Nafees et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2008)
The NICE cost-effectiveness threshold - What it is and what that means
Christopher McCabe et al.
PHARMACOECONOMICS (2008)
Cost-effectiveness of hepatic artery infusion for metastatic colorectal cancer (CALGB 9481)
JC Weeks et al.
VALUE IN HEALTH (2005)
Risk factors contributing to early and date phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy
H Imamura et al.
JOURNAL OF HEPATOLOGY (2003)
Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma
M Minagawa et al.
ANNALS OF SURGERY (2003)
分享论文
